Claudia Milena Trujillo-Vargas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Claudia Milena Trujillo-Vargas has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
K. J. Erb
Center for Infectious Diseases, University of Würzburg, Würzburg, Germany
2 shared publicationsA. Palmetshofer
Institute of Pathology, University of Würzburg, Würzburg, Germany
1 shared publicationAlois Palmetshofer
1 shared publicationChristoph Berberich
1 shared publicationG. Hansen
Martin-Luther-University Halle-Wittenberg, Halle, Germany
1 shared publicationG. Wohlleben
Center for Infectious Diseases, University of Würzburg, Würzburg, Germany
1 shared publication
Latest Publications
- 24 August 2005
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 35 (8) , 1003-1013
Vaccinations with T‐helper type 1 directing adjuvants have different suppressive effects on the development of allergen‐induced T‐helper type 2 responses
Summary: Background Allergen‐induced T‐helper type 2 (Th2) responses can be inhibited with Th1 directing vaccines. However, studies comparing the efficacy of the different adjuvants have not been performed in detail.Objective For this reason we compare the effects of live Bacillus–Calmette–Guerin(BCG), heat‐killed (hk)‐BCG, CpG‐ODN (oligodeoxynucleotide) or PPD on the development of allergen‐induced Th2 responses in mice.Methods Ovalbumin (OVA)‐specific allergic responses were induced in C57BL/6 mice by two intraperitoneally (i.p.) applications of OVA/alum followed by the intranasal challenge with OVA. The different Th1‐inducing adjuvants were applied to the mice together with OVA/alum i.p. during the OVA‐sensitization period and, subsequently, different parameters of allergic immune responses were evaluated.Results All the adjuvants were effective in inhibiting the development of allergen‐induced airway eosinophilia, mucous production and, with the exception of PPD, also airway hyper‐reactivity, when they were applied together with OVA/alum. However, allergen‐specific IgG1 and IgE serum levels were only reduced in live BCG‐ and PPD‐treated mice. Suppression of airway eosinophilia was not observed in IFN‐γ‐ or IL‐12‐deficient mice (hk‐BCG, CpG‐ODN and PPD). Interestingly, live BCG was still able to suppress allergen‐induced Th2 responses in the absence of either IFN‐γ or IL‐12. When mice vaccinated with the different adjuvants together with OVA/alum were subjected to a second period of OVA/alum immunization, only live and hk‐BCG were able to efficiently suppress the development of airway inflammation. This effect could be adoptively transferred by splenic CD4+ T cells.Conclusions Taken together our data suggest that live BCG>hk‐BCG>CpG‐ODN >PPD are effective in suppressing allergen‐induced Th2 responses. The degree of suppression and the component of the Th2 response affected (airway inflammation vs. the production of allergen‐specific IgE and IgG1) were dependent upon the adjuvant used and how it was applied. Our results contribute to the design of novel vaccines protecting humans from developing allergic disorders.
- 24 August 2005
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 35 (8) , 1003-1013
Vaccinations with T‐helper type 1 directing adjuvants have different suppressive effects on the development of allergen‐induced T‐helper type 2 responses
Summary: Background Allergen‐induced T‐helper type 2 (Th2) responses can be inhibited with Th1 directing vaccines. However, studies comparing the efficacy of the different adjuvants have not been performed in detail.Objective For this reason we compare the effects of live Bacillus–Calmette–Guerin(BCG), heat‐killed (hk)‐BCG, CpG‐ODN (oligodeoxynucleotide) or PPD on the development of allergen‐induced Th2 responses in mice.Methods Ovalbumin (OVA)‐specific allergic responses were induced in C57BL/6 mice by two intraperitoneally (i.p.) applications of OVA/alum followed by the intranasal challenge with OVA. The different Th1‐inducing adjuvants were applied to the mice together with OVA/alum i.p. during the OVA‐sensitization period and, subsequently, different parameters of allergic immune responses were evaluated.Results All the adjuvants were effective in inhibiting the development of allergen‐induced airway eosinophilia, mucous production and, with the exception of PPD, also airway hyper‐reactivity, when they were applied together with OVA/alum. However, allergen‐specific IgG1 and IgE serum levels were only reduced in live BCG‐ and PPD‐treated mice. Suppression of airway eosinophilia was not observed in IFN‐γ‐ or IL‐12‐deficient mice (hk‐BCG, CpG‐ODN and PPD). Interestingly, live BCG was still able to suppress allergen‐induced Th2 responses in the absence of either IFN‐γ or IL‐12. When mice vaccinated with the different adjuvants together with OVA/alum were subjected to a second period of OVA/alum immunization, only live and hk‐BCG were able to efficiently suppress the development of airway inflammation. This effect could be adoptively transferred by splenic CD4+ T cells.Conclusions Taken together our data suggest that live BCG>hk‐BCG>CpG‐ODN >PPD are effective in suppressing allergen‐induced Th2 responses. The degree of suppression and the component of the Th2 response affected (airway inflammation vs. the production of allergen‐specific IgE and IgG1) were dependent upon the adjuvant used and how it was applied. Our results contribute to the design of novel vaccines protecting humans from developing allergic disorders.
- 1 July 2005
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 137 (3) , 219-228
Mice Vaccinated with Allergen-Pulsed Myeloid Dendritic Cells Are Not Protected from Developing Allergen-Induced Th2 Responses
Background: Dendritic cells (DC) play a decisive role in the induction of allergen-induced Th1 and Th2 responses. Since the induction of allergen-specific Th1 responses has shown to inhibit allergen-induced Th2-type inflammation, in this study we investigated whether manipulated myeloid-derived DC pulsed with the specific allergen would predominantly induce allergen-specific Th1 responses thereby reducing the development of Th2 responses. Methods: Murine bone marrow (BM)-DC were generated and pulsed with ovalbumin (OVA) and CpG oligodeoxynucleotides (CpG-ODN). Langerhans cells (LC) were also isolated and pulsed in vitro with OVA. Subsequently, mice were vaccinated intravenously with either CpG/OVA-pulsed BM-DC or OVA-pulsed LC, and the protocol to induce OVA-specific Th2 responses using OVA/alum sensitization was initiated. Airway inflammation and OVA-specific serum antibody levels were evaluated 6 days after the intranasal challenge with OVA. Results: The application ofCpG/OVA-pulsed BM-DC was unable to reduce airway eosinophilia and inflammation in OVA/alum-immunized mice. OVA-specific IgG1 or IgE serum levels were also not reduced. The experiments using LC pulsed with OVA yielded similar results. However, mice vaccinated with CpG/OVA-pulsed BM-DC had greatly enhanced levels of serum OVA-specific IgG2a, suggesting the induction of allergen-specific Th1 responses in vivo. Moreover, allergen-induced mast cell degranulation was decreased using this approach. Conclusions: Taken together, our results demonstrated that the vaccination with OVA-pulsed BM-DC matured with CpG-ODN or OVA-pulsed LC did not result in a reduction in allergen-specific Th2 responses in a murine model of severe atopic asthma. Other DC-based vaccination strategies should be evaluated in order to prevent the development of allergic disorders.
- 1 July 2005
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 137 (3) , 219-228
Mice Vaccinated with Allergen-Pulsed Myeloid Dendritic Cells Are Not Protected from Developing Allergen-Induced Th2 Responses
Background: Dendritic cells (DC) play a decisive role in the induction of allergen-induced Th1 and Th2 responses. Since the induction of allergen-specific Th1 responses has shown to inhibit allergen-induced Th2-type inflammation, in this study we investigated whether manipulated myeloid-derived DC pulsed with the specific allergen would predominantly induce allergen-specific Th1 responses thereby reducing the development of Th2 responses. Methods: Murine bone marrow (BM)-DC were generated and pulsed with ovalbumin (OVA) and CpG oligodeoxynucleotides (CpG-ODN). Langerhans cells (LC) were also isolated and pulsed in vitro with OVA. Subsequently, mice were vaccinated intravenously with either CpG/OVA-pulsed BM-DC or OVA-pulsed LC, and the protocol to induce OVA-specific Th2 responses using OVA/alum sensitization was initiated. Airway inflammation and OVA-specific serum antibody levels were evaluated 6 days after the intranasal challenge with OVA. Results: The application ofCpG/OVA-pulsed BM-DC was unable to reduce airway eosinophilia and inflammation in OVA/alum-immunized mice. OVA-specific IgG1 or IgE serum levels were also not reduced. The experiments using LC pulsed with OVA yielded similar results. However, mice vaccinated with CpG/OVA-pulsed BM-DC had greatly enhanced levels of serum OVA-specific IgG2a, suggesting the induction of allergen-specific Th1 responses in vivo. Moreover, allergen-induced mast cell degranulation was decreased using this approach. Conclusions: Taken together, our results demonstrated that the vaccination with OVA-pulsed BM-DC matured with CpG-ODN or OVA-pulsed LC did not result in a reduction in allergen-specific Th2 responses in a murine model of severe atopic asthma. Other DC-based vaccination strategies should be evaluated in order to prevent the development of allergic disorders.
- 1 September 2002
- Published by Wiley in Parasite Immunology
- Vol. 24 (9-10) , 455-462
Endemically exposed asymptomatic individuals show no increase in the specific Leishmania (Viannia) panamensis‐Th1 immune response in comparison to patients with localized cutaneous leishmaniasis
SUMMARY: In Colombia, most cases of human cutaneous leishmaniasis are caused by Leishmania (Viannia) panamensis. Interestingly, up to 30% of the exposed population do not suffer from clinical leishmaniasis although it is likely that they are continuously infected with Leishmania parasites. Since it is believed that the induction of efficient Th1 immune responses protects against Leishmania infections both in humans and in animal models, we determined if endemically exposed asymptomatics showed stronger Leishmania‐specific Th1 immune responses than patients with active localized cutaneous leishmaniasis (LCL). We found that Montenegro skin test responses were slightly higher among asymptomatic individuals compared to patients suffering from LCL. However, PBMC from patients with LCL showed similar Leishmania‐specific proliferative responses compared to PBMC from asymptomatic individuals. Furthermore, PBMC from both groups also secreted similar amounts of IFN‐γ, IL‐12p40 and IL‐10 after in vitro exposure to L. panamensis. No IL‐4 was detected in the supernatants. Taken together our results suggest that lack of LCL development in endemically exposed asymptomatics cannot be explained by stronger systemic anti‐Leishmania Th1 immune responses or decreased Th2 responses in these individuals in comparison to individuals who develop LCL. It may be possible that other mechanisms are responsible for resistance to cutaneous leishmaniasis in Colombia in endemically exposed asymptomatics.
- 1 September 2002
- Published by Wiley in Parasite Immunology
- Vol. 24 (9-10) , 455-462
Endemically exposed asymptomatic individuals show no increase in the specific Leishmania (Viannia) panamensis‐Th1 immune response in comparison to patients with localized cutaneous leishmaniasis
SUMMARY: In Colombia, most cases of human cutaneous leishmaniasis are caused by Leishmania (Viannia) panamensis. Interestingly, up to 30% of the exposed population do not suffer from clinical leishmaniasis although it is likely that they are continuously infected with Leishmania parasites. Since it is believed that the induction of efficient Th1 immune responses protects against Leishmania infections both in humans and in animal models, we determined if endemically exposed asymptomatics showed stronger Leishmania‐specific Th1 immune responses than patients with active localized cutaneous leishmaniasis (LCL). We found that Montenegro skin test responses were slightly higher among asymptomatic individuals compared to patients suffering from LCL. However, PBMC from patients with LCL showed similar Leishmania‐specific proliferative responses compared to PBMC from asymptomatic individuals. Furthermore, PBMC from both groups also secreted similar amounts of IFN‐γ, IL‐12p40 and IL‐10 after in vitro exposure to L. panamensis. No IL‐4 was detected in the supernatants. Taken together our results suggest that lack of LCL development in endemically exposed asymptomatics cannot be explained by stronger systemic anti‐Leishmania Th1 immune responses or decreased Th2 responses in these individuals in comparison to individuals who develop LCL. It may be possible that other mechanisms are responsible for resistance to cutaneous leishmaniasis in Colombia in endemically exposed asymptomatics.